Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

FP6

MYELOMA SURVIVAL Résumé de rapport

Project ID: 46446
Financé au titre de: FP6-MOBILITY
Pays: Israel

Final Activity Report Summary - MYELOMA SURVIVAL (Identification of Factors that Promote the Survival of Multiple Myeloma)

Multiple myeloma (MM) is an incurable devastating cancer responsible for approximately 1-2% of lethality from cancer. MM is a unique type of cancer because it arises from a special cell type called plasma cell. Normally plasma cells are responsible for generating antibodies. They reside in the bone marrow and their numbers are carefully regulated. However, in processes that we do not fully understand, a single plasma cell loose its regulation, starts to proliferate uncontrollably and yields after several years MM. Because of the uniqueness of this disease, we hypothesised that MM utilise special biochemical reactions that allow it to proliferate and maintain antibody secretion. The main objective of this study was to identify biochemical processes that promote the survival of MM and plasma cells with the hope that inhibition of these pathways may result in novel therapeutic modalities to MM.

In brief, we discovered that synthesis of special lipid molecules in plasma cells, termed ceramides, plays an important element in plasma cells and not in other cell types. In plasma cells ceramide synthesis supports antibody production. In a paper published in the Journal of Immunology we described that treatment of plasma cells with an inhibitor for ceramide synthesis called fumonisin B1 results in inhibition of antibody production and aberrations in protein modifications. If true also to MM, we believe that this discovery may have an important meaning for MM treatment.

A second discovery we made concerned the transcription factor XBP-1. This factor is necessary for generation of plasma cells and plays an important role in the survival of MM. We previously showed that XBP-1 is degraded by the proteasome in seconds. We hypothesised that the mechanism of XBP-1 degradation is unusual and should be looked at in more details. In a paper submitted to FEBS letters and is currently under revision, we show that XBP-1 directly binds the proteasome and this interaction is mediated by multiple contact sites. The direct interaction with the proteasome is sufficient to promote XBP-1 degradation in vitro. Other projects are on-going in the lab that looks at the control of protein synthesis in plasma cells and characterisation of apoptosis in MM.

Contact

Israel RINGEL
Tél.: 972-2-6758620
Fax: 972-2-6758741
E-mail